Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-19 · accession 0000882796-25-000041 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-23 | 2025-12-22 | BCRX | Gayer Charles K | Pres, CCO | M - OptEx | $5.01 | +74.2K | 902.6K | +9% | +$371.9K |
| D | 2025-12-23 | 2025-12-19 | BCRX | Gayer Charles K | Pres, CCO | F - Tax | $7.41 | -11.5K | 878.4K | -1% | -$85.0K |
| DM | 2025-12-23 | 2025-12-22 | BCRX | Gayer Charles K | Pres, CCO | M - OptEx | $0.00 | -74.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-22 | M | A | 50,000 | $5.51 | 952,583 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-22 | M | A | 14,142 | $3.22 | 892,492 | D | — | — | |
| 3 | Common | Common Stock | 2025-12-19 | F | D | 11,477 | $7.41 | 878,350 | D | — | — | (F1) Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person. |
| 4 | Common | Common Stock | 2025-12-22 | M | A | 10,091 | $5.04 | 902,583 | D | — | — | |
| 5 | Derivative | Emp. Stock Option (Right to Buy) | 2025-12-22 | M | D | 10,091 | $0.00 | 17,409 | D | $5.04 · 2018-12-20 to 2027-12-20 | 10,091 Common Stock | (F2) The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| 6 | Derivative | Emp. Stock Option (Right to Buy) | 2025-12-22 | M | D | 50,000 | $0.00 | 0 | D | $5.51 · 2018-02-27 to 2027-02-27 | 50,000 Common Stock | (F2) The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| 7 | Derivative | Emp. Stock Option (Right to Buy) | 2025-12-22 | M | D | 14,142 | $0.00 | 0 | D | $3.22 · 2017-05-23 to 2026-05-23 | 14,142 Common Stock | (F2) The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |